QR-421a
PQ-421a-001
Phase 2 small_molecule completed
Quick answer
QR-421a for Retinitis Pigmentosa is a Phase 2 program (small_molecule) at ProQR Therapeutics N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ProQR Therapeutics N.V.
- Indication
- Retinitis Pigmentosa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed